Skip to main content

FDA Drug Recalls

Every FDA drug enforcement recall Public Health Trace has on record, republished from openFDA's official drug enforcement database. See Health Alerts for current, active recalls alongside outbreaks and advisories.

Drug recall information is sourced from the FDA's structured openFDA Enforcement Reports. Newly announced recalls may appear on FDA.gov before they become available in the structured dataset. See Methodology for how Public Health Trace imports and refreshes this data.

Filters
Recall details
Location
Date range
Clear filters

Showing 10,281–10,300 of 17,974 drug recalls

Drug Recall Terminated Historical recordClass I

PapaZen 3300 capsule, Proprietary Blend 1800mg, 1-capsule packets, distributed by FX Power San Diego, CA 92108, UPC 718122032587

by Gadget Island, Inc

Reason
Marketed without an Approved NDA/ANDA: undeclared Active Pharmaceutical Ingredients sildenafil, desmethyl carbodenafil and tadalafil.
Recall initiated
September 15, 2017
Reported by FDA
December 13, 2017
Distribution
Nationwide in the USA

View recall →

Drug Recall Terminated Historical recordClass I

RHINO 7 Platinum 5000, capsule, Proprietary Material: 750mg, 1-capsule packets, distributed by Fifty Shades Bayside, NY 11361, UPC 617135861224

by Gadget Island, Inc

Reason
Marketed without an Approved NDA/ANDA: undeclared Active Pharmaceutical Ingredients sildenafil, desmethyl carbodenafil and tadalafil.
Recall initiated
September 15, 2017
Reported by FDA
December 13, 2017
Distribution
Nationwide in the USA

View recall →

Drug Recall Terminated Historical recordClass I

Pravastatin Sodium Tablets, USP, 40 mg, 30-count bottle, Rx only, Packaged for: International Laboratories, LLC. St. Petersburg, FL 33710, NDC 54458-925-16

by International Laboratories, Inc.

Reason
Labeling: Label mix-up, the product labeled as Pravastatin sodium tablets 40 mg was filled with Bupropion hydrochloride XL Tablets 300 mg.
Recall initiated
August 7, 2017
Reported by FDA
December 13, 2017
Distribution
U.S.A. nationwide and Puerto Rico

View recall →

Drug Recall Terminated Historical recordClass II

Paroxetine Tablets USP, 30 mg, a) 30 count (NDC 68382-099-06), b) 500 count (NDC 68382-099-05), and c) 1000 count (NDC 68382-099-10) count bottles, Rx Only, Manufactured by: Cadila Healthcare Ltd, Ahmedabad, India Distributed by: Zydus Pharmaceuticals USA, Inc., Pennington, NJ 08534

by Zydus Pharmaceuticals USA Inc

Reason
Presence of Foreign Tablets/Capsules: Risperidone Tablets were found in bottle of Paroxetine Tablets
Recall initiated
November 20, 2017
Reported by FDA
December 6, 2017
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

Vertra Elemental Resistance (Octyl Methoxycinnamate 6%, Oxybenzone 5%, Titanium Dioxide 6.3%, Zinc Oxide 9.9%) Sun Protection Cream, SPF 50+, Net. Wt. 2.8 oz (80 g) tube in a carton, Distributed by Vertra/EAI-JR286, 20100 S Vermont Ave, Torrance, CA 90502, Made In Australia, UPC 8 94140 00103 0.

by EAI-JR286 INC

Reason
CGMP Deviations: products manufactured in a manner that may impact product quality that includes but is not limited to failed viscosity.
Recall initiated
November 28, 2017
Reported by FDA
December 6, 2017
Distribution
Nationwide in the USA and Puerto Rico.

View recall →

Drug Recall Terminated Historical recordClass II

Levetiracetam Oral Solution, USP, 100 mg/mL, packaged in a 16 fl oz (473 mL) bottle, Rx only, Manufactured for: Camber Pharmaceuticals, Inc., Piscataway, NJ 08854, By: Hetero, Hetero Labs Limited, Jeedimetla,Hyderabad - 500 055, India, NDC 31722-574-47

by Hetero Labs, Ltd. - Unit III

Reason
Presence of foreign substance (screw)
Recall initiated
October 12, 2017
Reported by FDA
December 6, 2017
Distribution
NJ

View recall →

Drug Recall Terminated Historical recordClass II

Liothyronine Sodium Tablets, USP 25 mcg ,100-count bottles, Rx Only, Distributed by Perrigo Minneapolis, MN 55427, NDC 0574-0222-01

by Mayne Pharma Inc

Reason
Failed Dissolution Specifications.
Recall initiated
November 9, 2017
Reported by FDA
December 6, 2017
Distribution
Nationwide within USA

View recall →

Drug Recall Terminated Historical recordClass III

Duloxetine Delayed-Release Capsules USP, 30 mg, 30-count bottles, Rx Only, Manufactured for: Lupin Pharmaceuticals, Inc. Baltimore, Maryland 21202 United States, Manufactured by: Lupin Limited Goa 403 722 India, NDC 68180-295-06, UPC 368180295068

by Lupin Pharmaceuticals Inc.

Reason
Failed Dissolution Specification
Recall initiated
November 21, 2017
Reported by FDA
December 6, 2017
Distribution
Nationwide within the United States

View recall →

Drug Recall Terminated Historical recordClass II

Clozapine Tablets USP, 100 mg, 500 count bottles, Rx only, Manufactured in Israel by: TEVA PHARMACEUTICALS IND, LTD, Jerusalem Israel, Manufactured For: TEVA PHARMACEUTICALS USA, North Wales, PA, NDC 00093-7772-05

by Teva Pharmaceuticals USA

Reason
Failed Tablet/Capsule Specifications; potential presence of broken tablets.
Recall initiated
November 9, 2017
Reported by FDA
December 6, 2017
Distribution
Nationwide

View recall →

Drug Recall Terminated Historical recordClass II

No.1 Faiza Beauty Cream Manufactured by: Poonia Brothers (Pak), Gujranwala, Distributed by NEW RELIANCE TRADING, INC., 5563 59th St., Maspeth, New York, 11378-2358, UPC 8993138993349, 5842109854239.

by NEW RELIANCE TRADING, INC.

Reason
Marketed Without an Approved NDA/ANDA
Recall initiated
October 6, 2017
Reported by FDA
December 6, 2017
Distribution
NY

View recall →

Drug Recall Terminated Historical recordClass III

Dexamethasone Sodium Phosphate Injection, USP, 20 mg/5 mL (4 mg/mL), 5 mL Vials (NDC 0641-6146-01), packaged in 25 x 5 mL Vials per shelf pack (NDC 0641-6146-25), Rx Only, Manufactured by WEST-WARD, Eatontown, NJ 07724 USA.

by West-Ward Pharmaceuticals Corp.

Reason
Failed Impurities/Degradation Specifications: high out of specification results for Dexamethasone adduct (related compound).
Recall initiated
November 6, 2017
Reported by FDA
November 29, 2017
Distribution
Nationwide in the USA and Puerto Rico

View recall →

Drug Recall Terminated Historical recordClass III

Dexamethasone Sodium Phosphate Injection, USP, 4 mg/mL, 1 mL Vials (NDC 0641-6145-01), packaged in 25 x 1 mL Vials per shelf pack (NDC 0641-6145-25), Rx Only, Manufactured by WEST-WARD, Eatontown, NJ 07724 USA.

by West-Ward Pharmaceuticals Corp.

Reason
Failed Impurities/Degradation Specifications: high out of specification results for Dexamethasone adduct (related compound).
Recall initiated
November 6, 2017
Reported by FDA
November 29, 2017
Distribution
Nationwide in the USA and Puerto Rico

View recall →

Drug Recall Terminated Historical recordClass II

Pravastatin Sodium USP, tablets, 40 mg, 90-count bottle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202, NDC 68180-487-09

by Lupin Limited

Reason
Presence of foreign tablets/capsules: This product lot is being recalled due to a pharmacy complaint where one Duloxetine Delayed Release Capsule, 30mg was found in a Pravastatin Sodium Tablets USP, 40mg bottle.
Recall initiated
November 17, 2017
Reported by FDA
November 29, 2017
Distribution
Product was distributed throughout the United States, including Puerto Rico.

View recall →

Drug Recall Terminated Historical recordClass II

Paroxetine Tablets, USP, 30mg, 100 tablets (10 x 10) , Rx Only, Distributed by: American Health Packaging, Columbus, Ohio 43217. Columbus, Ohio 43217, NDC 68084-046-01

by Amerisource Health Services

Reason
Presence of Foreign Tablets/Capsules.
Recall initiated
October 24, 2017
Reported by FDA
November 29, 2017
Distribution
Nationwide in the USA

View recall →

Drug Recall Terminated Historical recordClass II

Extra Strength Naturally HL Hemorrhoid Numbing with Lidocaine, (lidocaine HCL 4%), 1/2 oz Balm (NDC 69804-014-06), and 2 oz Balm(NDC 69804-014-03), Manufactured by Pain Relief Naturally, www.Naturally HL.com

by Ridge Properties, LLC

Reason
GMP Deviations: inadequate manufacturing control processes
Recall initiated
November 3, 2017
Reported by FDA
November 29, 2017
Distribution
Product distributed throughout United States.

View recall →

Drug Recall Terminated Historical recordClass II

Extra Strength Naturally HL Liquid Hemorrhoid Relief Gel, (lidocaine HCL 4%), 1/2 oz Liquid Gel (NDC 69804-024-13), 1 oz Liquid Gel (NDC 69804-024-14), 2 oz Liquid Gel (NDC 69804-024-15), 4 oz Liquid Gel (NDC 69804-024-16) bottles, Manufactured by Pain Relief Naturally, www.Naturally HL.com

by Ridge Properties, LLC

Reason
GMP Deviations: inadequate manufacturing control processes
Recall initiated
November 3, 2017
Reported by FDA
November 29, 2017
Distribution
Product distributed throughout United States.

View recall →

Drug Recall Terminated Historical recordClass II

Extra Strength Naturally HL Hemorrhoid Numbing Spray with Lidocaine, (lidocaine HCL 4%), 1/2 oz Spray (NDC 69804-015-08), 1 oz Spray (NDC 69804-015-07), 2 oz Spray (NDC 69804-015-01) and 4 oz Spray (NDC 69804-015-04) bottles, Manufactured by Pain Relief Naturally, www.Naturally HL.com

by Ridge Properties, LLC

Reason
GMP Deviations: inadequate manufacturing control processes
Recall initiated
November 3, 2017
Reported by FDA
November 29, 2017
Distribution
Product distributed throughout United States.

View recall →

Drug Recall Terminated Historical recordClass II

Extra Strength PreTAT by TAT BALM Gel, (lidocaine HCL 4%), 1/2 oz Gel (NDC 69804-018-09), 1 oz Gel (NDC 69804-018-10) , 2 oz Gel (NDC 69804-018-11), and 4 oz Gel (NDC 69804-018-12) jars, Manufactured by Pain Relief Naturally, www.Naturally HL.com

by Ridge Properties, LLC

Reason
GMP Deviations: inadequate manufacturing control processes
Recall initiated
November 3, 2017
Reported by FDA
November 29, 2017
Distribution
Product distributed throughout United States.

View recall →

Drug Recall Terminated Historical recordClass II

Extra Strength Naturally HL Bed Sore Relief Cream with Added Lidocaine, (lidocaine HCL 4%), 1/2 oz Balm(NDC 69804-008-06), 1 oz Balm (NDC 69804-008-05), 2 oz Balm(NDC 69804-008-02), and 4 oz Balm(NDC 69804-008-03), Manufactured by Pain Relief Naturally, www.Naturally HL.com

by Ridge Properties, LLC

Reason
GMP Deviations: inadequate manufacturing control processes
Recall initiated
November 3, 2017
Reported by FDA
November 29, 2017
Distribution
Product distributed throughout United States.

View recall →

Drug Recall Terminated Historical recordClass II

Lorazepam Tablets, USP CIV, 0.5 mg, 500-count bottle, Rx Only, Manufactured by: Leading Pharma, LLC Fairfield, NJ 07004 NDC 69315-904-05

by Leading Pharma, LLC

Reason
Labeling: Label Error on Declared Strength. Bottle labeled as 0.5 mg tablets contained 1mg tablets of lorazepam
Recall initiated
September 28, 2017
Reported by FDA
November 29, 2017
Distribution
Nationwide in the USA

View recall →

Data last updated:

This information is republished from FDA's Recall Enterprise System through openFDA. Public Health Trace does not verify or supplement it, is not affiliated with the FDA, and does not provide medical advice -- always follow the guidance of your pharmacist, physician, or the recalling company for any medication you take. Read the full medical disclaimer.